Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1-Year After Adult Heart Transplant.

IF 4 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Pharmacotherapy Pub Date : 2026-01-01 Epub Date: 2025-11-11 DOI:10.1002/phar.70073
Caroline Chen, Zeina Jedeon, Abhishek Jaiswal, David A Baran, Katrina Etts, William L Baker
{"title":"Utilizing Machine Learning to Identify Predictors of Corticosteroid Discontinuation 1-Year After Adult Heart Transplant.","authors":"Caroline Chen, Zeina Jedeon, Abhishek Jaiswal, David A Baran, Katrina Etts, William L Baker","doi":"10.1002/phar.70073","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To use machine learning methods to identify factors associated with corticosteroid (CS) discontinuation 1 year after adult heart transplantation (HT).</p><p><strong>Design: </strong>Retrospective, observational, cohort study.</p><p><strong>Data source: </strong>This study used data from the United Network for Organ Sharing (UNOS) database.</p><p><strong>Patients: </strong>We included adults (age ≥ 18 years) who underwent their first HT between January 2000 and December 2023 in the UNOS database with follow-up through December 2024, who were discharged on a CS.</p><p><strong>Measurements: </strong>We divided the cohort into those with or without CS at 1-year post-transplant follow-up. We used the eXtreme Gradient Boosting (XGBoost) algorithm to build a model predicting CS discontinuation at 1 year. Relevant recipient, donor, and transplant variables were included to train the model, with Shapley Additive Explanations (SHAP) used to identify and interpret the most important and predictive features.</p><p><strong>Results: </strong>We identified 72,730 HT recipients; 13,017 (17.9%) had CS discontinued within the first year. Compared with the CS cessation group, those who continued CS were more likely to have had a lower BMI, lower ischemic etiology of cardiomyopathy, lower intra-aortic balloon pump (IABP) and left ventricular assist device (LVAD) use before HT, better renal function, and sustained longer donor ischemic time. Model performance was strong, with an area under the curve of 0.854 (95% confidence interval: 0.848-0.861). Lower average transplant center volume (number of transplants per year), shorter donor ischemic time, and LVAD use at transplant predicted CS discontinuation.</p><p><strong>Conclusions: </strong>In a large national database, utilizing novel ML modeling techniques, we identified annual transplant center volume, donor ischemia time, and LVAD use at the time of HT as the best predictors of CS discontinuation 1 year after HT.</p>","PeriodicalId":20013,"journal":{"name":"Pharmacotherapy","volume":" ","pages":"e70073"},"PeriodicalIF":4.0000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/phar.70073","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/11/11 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To use machine learning methods to identify factors associated with corticosteroid (CS) discontinuation 1 year after adult heart transplantation (HT).

Design: Retrospective, observational, cohort study.

Data source: This study used data from the United Network for Organ Sharing (UNOS) database.

Patients: We included adults (age ≥ 18 years) who underwent their first HT between January 2000 and December 2023 in the UNOS database with follow-up through December 2024, who were discharged on a CS.

Measurements: We divided the cohort into those with or without CS at 1-year post-transplant follow-up. We used the eXtreme Gradient Boosting (XGBoost) algorithm to build a model predicting CS discontinuation at 1 year. Relevant recipient, donor, and transplant variables were included to train the model, with Shapley Additive Explanations (SHAP) used to identify and interpret the most important and predictive features.

Results: We identified 72,730 HT recipients; 13,017 (17.9%) had CS discontinued within the first year. Compared with the CS cessation group, those who continued CS were more likely to have had a lower BMI, lower ischemic etiology of cardiomyopathy, lower intra-aortic balloon pump (IABP) and left ventricular assist device (LVAD) use before HT, better renal function, and sustained longer donor ischemic time. Model performance was strong, with an area under the curve of 0.854 (95% confidence interval: 0.848-0.861). Lower average transplant center volume (number of transplants per year), shorter donor ischemic time, and LVAD use at transplant predicted CS discontinuation.

Conclusions: In a large national database, utilizing novel ML modeling techniques, we identified annual transplant center volume, donor ischemia time, and LVAD use at the time of HT as the best predictors of CS discontinuation 1 year after HT.

利用机器学习识别成人心脏移植后1年皮质类固醇停药的预测因素。
目的:利用机器学习方法识别成人心脏移植(HT)术后1年停用皮质类固醇(CS)的相关因素。设计:回顾性、观察性、队列研究。数据来源:本研究使用的数据来自美国器官共享网络(UNOS)数据库。患者:我们纳入了在UNOS数据库中于2000年1月至2023年12月期间接受第一次HT治疗的成人(年龄≥18岁),随访至2024年12月,均为CS出院患者。测量:我们在移植后1年随访中将队列分为有或没有CS的组。我们使用极端梯度增强(XGBoost)算法建立了一个预测1年CS停止的模型。相关的受体、供体和移植变量被纳入训练模型,Shapley加性解释(SHAP)用于识别和解释最重要的预测性特征。结果:我们确定了72730名HT受体;13017例(17.9%)患者在第一年内停用了CS。与停止CS组相比,继续CS组更有可能在HT前具有较低的BMI,较低的缺血性心肌病病因,较低的主动脉内球囊泵(IABP)和左心室辅助装置(LVAD)的使用,较好的肾功能和持续较长的供体缺血时间。模型性能较好,曲线下面积为0.854(95%置信区间为0.848 ~ 0.861)。较低的平均移植中心容量(每年移植数量)、较短的供体缺血时间和移植时LVAD的使用预示着CS的停止。结论:在一个大型的国家数据库中,利用新颖的ML建模技术,我们确定了移植中心年容量、供体缺血时间和移植时LVAD使用情况是移植后1年CS停止的最佳预测因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Pharmacotherapy
Pharmacotherapy 医学-药学
CiteScore
7.80
自引率
2.40%
发文量
93
审稿时长
4-8 weeks
期刊介绍: Pharmacotherapy is devoted to publication of original research articles on all aspects of human pharmacology and review articles on drugs and drug therapy. The Editors and Editorial Board invite original research reports on pharmacokinetic, bioavailability, and drug interaction studies, clinical trials, investigations of specific pharmacological properties of drugs, and related topics.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书